Your browser doesn't support javascript.
loading
Antineoplastic treatment class modulates COVID-19 mRNA-BNT162b2 vaccine immunogenicity in cancer patients: a secondary analysis of the prospective Vax-On study.
Ruggeri, E M; Nelli, F; Fabbri, A; Onorato, A; Giannarelli, D; Giron Berrios, J R; Virtuoso, A; Marrucci, E; Mazzotta, M; Schirripa, M; Panichi, V; Pessina, G; Signorelli, C; Chilelli, M G; Primi, F; Natoni, F; Fazio, S; Silvestri, M A.
Afiliación
  • Ruggeri EM; Department of Oncology and Hematology, Medical Oncology Unit, Central Hospital of Belcolle, Viterbo, Italy.
  • Nelli F; Department of Oncology and Hematology, Medical Oncology Unit, Central Hospital of Belcolle, Viterbo, Italy. Electronic address: fabrizio.nelli@asl.vt.it.
  • Fabbri A; Department of Oncology and Hematology, Medical Oncology Unit, Central Hospital of Belcolle, Viterbo, Italy.
  • Onorato A; Department of Oncology and Hematology, Medical Oncology Unit, Central Hospital of Belcolle, Viterbo, Italy.
  • Giannarelli D; Clinical Trial Center, Biostatistics and Bioinformatics Unit, Scientific Direction, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
  • Giron Berrios JR; Department of Oncology and Hematology, Medical Oncology Unit, Central Hospital of Belcolle, Viterbo, Italy.
  • Virtuoso A; Department of Oncology and Hematology, Medical Oncology Unit, Central Hospital of Belcolle, Viterbo, Italy.
  • Marrucci E; Department of Oncology and Hematology, Medical Oncology Unit, Central Hospital of Belcolle, Viterbo, Italy.
  • Mazzotta M; Department of Oncology and Hematology, Medical Oncology Unit, Central Hospital of Belcolle, Viterbo, Italy.
  • Schirripa M; Department of Oncology and Hematology, Medical Oncology Unit, Central Hospital of Belcolle, Viterbo, Italy.
  • Panichi V; Department of Oncology and Hematology, Microbiology and Virology Unit, Central Hospital of Belcolle, Viterbo, Italy.
  • Pessina G; Department of Oncology and Hematology, Molecular Biology and Covid Diagnostics, Central Hospital of Belcolle, Viterbo, Italy.
  • Signorelli C; Department of Oncology and Hematology, Medical Oncology Unit, Central Hospital of Belcolle, Viterbo, Italy.
  • Chilelli MG; Department of Oncology and Hematology, Medical Oncology Unit, Central Hospital of Belcolle, Viterbo, Italy.
  • Primi F; Department of Oncology and Hematology, Medical Oncology Unit, Central Hospital of Belcolle, Viterbo, Italy.
  • Natoni F; Department of Oncology and Hematology, Molecular Biology and Covid Diagnostics, Central Hospital of Belcolle, Viterbo, Italy.
  • Fazio S; Department of Oncology and Hematology, Molecular Biology and Covid Diagnostics, Central Hospital of Belcolle, Viterbo, Italy.
  • Silvestri MA; Department of Oncology and Hematology, Microbiology and Virology Unit, Central Hospital of Belcolle, Viterbo, Italy.
ESMO Open ; 7(1): 100350, 2022 Feb.
Article en En | MEDLINE | ID: mdl-34942438
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Inmunidad Humoral / Glicoproteína de la Espiga del Coronavirus / Inmunogenicidad Vacunal / COVID-19 / Vacuna BNT162 / Neoplasias / Antineoplásicos Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: ESMO Open Año: 2022 Tipo del documento: Article País de afiliación: Italia
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Inmunidad Humoral / Glicoproteína de la Espiga del Coronavirus / Inmunogenicidad Vacunal / COVID-19 / Vacuna BNT162 / Neoplasias / Antineoplásicos Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: ESMO Open Año: 2022 Tipo del documento: Article País de afiliación: Italia